To date, Dr. Faul has published more than 60 original peer-reviewed articles, which received over 10,000 citations. Dr. Faul’s research started to focus on studying the functions of FGF23 and klotho at the University of Miami Miller School of Medicine in 2008. Dr. Faul has co-designed the detection assay and purification technique for sKL as well as the approach to screen for FGFR4 inhibitors.
Bio
Dr. Faul is a cell biologist and an Associate Professor in the Division of Nephrology within the Department of Medicine and in the Department of Cell, Developmental and Integrative Biology at the University of Alabama at Birmingham (UAB). He is also a member of the Section of Cardio-Renal Physiology and Medicine and the Nephrology Research & Training Center as well as the Comprehensive Diabetes Center and the Comprehensive Cancer Center. Dr. Faul received his PhD from the Albert Einstein College of Medicine in New York City in 2005, where he studied the regulation of the kidney filter in the laboratory of Dr. Peter Mundel. His postdoctoral research at the Mount Sinai School of Medicine in NYC focused on studying specific mechanisms that are activated in the injured kidney and heart. In 2008, he moved as an Assistant Professor of Medicine and Cell Biology to the University of Miami Miller School of Medicine. It was there that Dr. Faul’s research started to focus on studying the functions of FGF23 and klotho, and their contributions to heart injury in animal models of CKD. In 2017, Dr. Faul moved to UAB to further focus on these research topics. He has co-designed the detection assay and purification technique for sKL as well as the approach to screen for FGFR4 inhibitors.
To date, Dr. Faul has published more than 60 original peer-reviewed articles, which received over 10,000 citations. He is on the editorial board of Kidney International and Scientific Reports. Dr. Faul has received research funding from the American Heart Association (AHA), the American Diabetes Association (ADA), the American Society of Nephrology (ASN), and the NephCure Foundation. Dr. Faul has received two R01 grants from the National Institutes of Health (NIH), with the goal to study the roles of FGF23 and klotho in CKD and associated heart injury. Dr. Faul also received several awards for his research, including the Gail Patrick Innovation Award from the ADA in 2016, the Stanley J. Glaser Foundation Research Award from University of Miami Miller School of Medicine in 2014, the Bernd Tersteegen Award from the Association for German Kidney Centers (Verband Deutsche Nierenzentren) in 2012, and the Carl W. Gottschalk Research Award from the ASN in 2012.